IDEXX Laboratories stock trades with a 39.69 price-to-earnings ratio
Published on 10/17/2026 at 22:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTrading levels and dates
- The valuation multiple stands at 39.69.
- Nasdaq closed at USD 560.36 on October 16, 2026.
- IDEXX Laboratories stock was last at EUR 498.20 at Lang & Schwarz on October 16, 2026 at 2:01 p.m. CEST, 0.65 percent above the Xetra close of October 16, 2026.
- Third-quarter results are scheduled for November 2, 2026.
A 39.69 price-to-earnings ratio frames IDEXX Laboratories (ISIN US45168D1046) after the latest completed US session. The Nasdaq-listed stock closed at USD 560.36 on October 16, 2026. IDEXX Laboratories was last at EUR 498.20 at Lang & Schwarz on October 16, 2026 at 2:01 p.m. CEST, 0.65 percent above the Xetra close of October 16, 2026 at EUR 495.00.
Valuation at 39.69
The price-to-earnings ratio puts the company at a clear valuation level alongside its recent operating performance. IDEXX Laboratories reported second-quarter 2026 revenue of USD 1.22 billion and net income of USD 338.41 million, while diluted earnings per share reached USD 4.27 for the period. The figures came from the standardized financial statement for the quarter ended June 30, 2026.
Price position in dollars
On Nasdaq, the October 16 close stood 11.94 percent above the 52-week low of USD 500.61 and 27.22 percent below the 52-week high of USD 769.98. The session range was USD 552.62 to USD 566.55, and volume reached 708,810 shares against an average of 546,512.
The market capitalization was USD 44.1 billion as of October 16, 2026. IDEXX provides veterinary diagnostics, software and related services, with reference laboratories, point-of-care systems and practice-management products forming the core of its offering.
Valuation and next date
In a release dated October 1, 2026, IDEXX Laboratories scheduled its third-quarter 2026 results for November 2, 2026, before the Nasdaq open. The company also scheduled an analyst conference call for 8:30 a.m. ET that day.
Comparison with peers
IDEXX Laboratories: plus 0.65 percent, P/E 39.69, market capitalization USD 44.1 billion.
Henry Schein (Nasdaq, USD): minus 0.70 percent, P/E 25.18, market capitalization USD 9.6 billion.
West Pharmaceutical Services (NYSE, USD): plus 0.26 percent, P/E 49.11, market capitalization USD 27.0 billion.
Euro quote and Xetra comparison
The euro quotation sits above the Xetra close used for the comparison, while the US close provides the primary-market level for the October 16 session. The next scheduled reporting date is November 2, 2026.
IDEXX Laboratories was last at EUR 498.20 at Lang & Schwarz on October 16, 2026 at 2:01 p.m. CEST, 0.65 percent above the Xetra close of October 16, 2026 at EUR 495.00. The further course of trading is shown by the continuously updated real-time quote of IDEXX Laboratories stock.
IDEXX Laboratories stock facts
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- WKN: 888210
- Ticker: IDXX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 16, 2026, 2:01 p.m. CEST): EUR 498.20
- Change versus Xetra close: plus 0.65 percent
- Xetra close (October 16, 2026): EUR 495.00
- Market capitalization: USD 44.1 billion (as of October 16, 2026)
- 52-week range: USD 500.61-769.98 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical Diagnostics and Research
- Index membership: S&P 500
- Next earnings date: November 2, 2026
Market context: Market report Nasdaq Composite.
